levofloxacin has been researched along with tranylcypromine in 2 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (tranylcypromine) | Trials (tranylcypromine) | Recent Studies (post-2010) (tranylcypromine) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 1,826 | 94 | 183 |
| Protein | Taxonomy | levofloxacin (IC50) | tranylcypromine (IC50) |
|---|---|---|---|
| Lysine-specific histone demethylase 1A | Homo sapiens (human) | 4.64 | |
| Cytochrome P450 1A1 | Homo sapiens (human) | 6.2 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 6.2 | |
| Cytochrome P450 2E1 | Homo sapiens (human) | 6.2 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 3.585 | |
| Cytochrome P450 2C8 | Homo sapiens (human) | 6.2 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 6.2 | |
| Cytochrome P450 2A6 | Homo sapiens (human) | 2.7133 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 3.38 | |
| Cytochrome P450 4B1 | Homo sapiens (human) | 6.2 | |
| Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | 0.078 | |
| Cytochrome P450 2B6 | Homo sapiens (human) | 6.4533 | |
| Cytochrome P450 3A5 | Homo sapiens (human) | 6.2 | |
| Cytochrome P450 2A7 | Homo sapiens (human) | 6.2 | |
| Amine oxidase [flavin-containing] A | Rattus norvegicus (Norway rat) | 0.29 | |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | 3.6436 | |
| Cytochrome P450 3A7 | Homo sapiens (human) | 6.2 | |
| Cytochrome P450 2F1 | Homo sapiens (human) | 6.2 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 3.0871 | |
| Cytochrome P450 2C18 | Homo sapiens (human) | 6.2 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 4.87 | |
| Cytochrome P450 2J2 | Homo sapiens (human) | 6.2 | |
| Cytochrome P450 4F2 | Homo sapiens (human) | 6.2 | |
| Cytochrome P450 4F8 | Homo sapiens (human) | 6.2 | |
| Cytochrome P450 4A11 | Homo sapiens (human) | 6.2 | |
| Cytochrome P450 4F3 | Homo sapiens (human) | 6.2 | |
| Cytochrome P450 1B1 | Homo sapiens (human) | 6.2 | |
| Cytochrome P450 2A13 | Homo sapiens (human) | 6.2 | |
| Cytochrome P450 4A22 | Homo sapiens (human) | 6.2 | |
| Vitamin D 25-hydroxylase | Homo sapiens (human) | 6.2 | |
| Cytochrome P450 2U1 | Homo sapiens (human) | 6.2 | |
| Cytochrome P450 2W1 | Homo sapiens (human) | 6.2 | |
| Cytochrome P450 2S1 | Homo sapiens (human) | 6.2 | |
| Cytochrome P450 3A43 | Homo sapiens (human) | 6.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
2 other study(ies) available for levofloxacin and tranylcypromine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |